The VHH Company™
Smaller – Better – Faster – Stronger
We work collaboratively with you, understanding your requirements and problem solving using our team’s combined experience of 100s of years in antibody research. Isogenica has 3 partnered assets into clinical development.
We develop proprietary LlamdA® VHH: highly versatile small format single domain antibodies, which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including two assets in clinical Phase 1 and one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
We with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.